News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
News 11 blockbuster drugs to look out for in 2025 Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
News Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
News FDA approves flurry of drugs ahead of holiday season The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.
News Novo Nordisk sheds billions in value on obesity data Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.
News Novo completes $16.5bn takeover of Catalent Novo Holdings' $16.5bn takeover of US CDMO Catalent has been completed, after months of debate over potential antitrust issues.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.